<DOC>
	<DOC>NCT00144573</DOC>
	<brief_summary>This is an open-label, clinical pharmacology study to evaluate the safety and PK of MRA in patients with RA with Renal Impairment.</brief_summary>
	<brief_title>Clinical Pharmacology Study of MRA in Patient With Rheumatoid Arthritis (RA) With Renal Impairment</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Inclusion criteria Patients who are diagnosed with RA according to the 1987 ACR (American College of Rheumatology) classification criteria Patients with RA at least 6 months prior to enrollment Patients with a creatinine clearance not less than 10 mL/min but no higher than 80 mL/min Exclusion criteria Patients with Class IV Steinbrocker functional impairment at enrollment Patients who are undergoing dialysis Patients who have been treated for the underlying disease with a biological agent, such as infliximab or etanercept, and have been receiving treatment with leflunomide, within 12 weeks before treatment with the investigational product</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2008</verification_date>
</DOC>